Latest Omeros Corporation Stories
-- 4Q 2014 net loss of $20.7 million, or $0.61 per share -- SEATTLE, March 16, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering,
SEATTLE, March 9, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics
- The Company Agrees to Physician Request to Continue Treatment of Patients with aHUS - SEATTLE, Feb.
DALLAS, December 15, 2014 /PRNewswire/ -- ReportsnReports.com adds Ocular Disorders: Rising Therapeutics, Technologies, and Devices 2014 market research report that covers
- Data Bode Well for Success of Ongoing Phase 2 Trial in Thrombotic Microangiopathies - SEATTLE, Nov.
-- Omidria(TM) U.S. Commercial Launch Planned for Early 2015 -- SEATTLE, Nov.